Navigation Links
Glysure Presents Successful Clinical Trial Results at ISICEM
Date:3/20/2012

OXFORD, England, March 20, 2012 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, announced that Dr Krishna Prasad is presenting the results of its Intensive Care Unit (ICU) Pilot Trial for the first time at the 32nd International Symposium on Intensive Care and Emergency Medicine (ISICEM) being held in Brussels, Belgium from March 20th - 23rd, 2012.

The data show that the optical fluorescence sensor can successfully measure blood glucose levels with a high degree of accuracy across a wide range of intensive care patients throughout their length of stay in the ICU.

The pioneering new research results being presented at ISICEM were collected from critically ill patients during GlySure's recent pilot ICU clinical trial. It is the first major clinical milestone for the venture capital backed medical technology company.  GlySure believes its continuous intravascular glucose monitoring system has the potential to improve outcomes for over 8 million ICU patients annually.

At ISICEM Principal Investigator Dr Krishna Prasad will present the data from eighteen ICU patients with a broad range of conditions and co-morbidities including cardiac surgery, cerebral trauma, sepsis, diabetes and hypertension.  All of the critically ill patients were monitored continuously and accurately for blood glucose levels throughout their length of stay in the ICU - up to 100 hours of continuous monitoring.

"Clinicians have been waiting for a continuous real-time blood glucose monitor to support implementation of Tight Glycemic Control protocols for much of the past decade," said Dr Prasad.  

GlySure CEO Chris Jones said: "We are very excited by the results of the pilot ICU clinical trial and are delighted to be able to share them for the first time at ISICEM. We are looking forward to beginning our European and US clinical regulatory trials and bringing this technology to market to support clinicians in realizing the promise of Tight Glycemic Control."

GlySure's presentation is entitled 'Accuracy of a Continuous Intravascular Glucose Monitor in ICU Patients'.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  GlySure was founded in 2006 and is based in Abingdon, Oxfordshire, England. http://www.glysure.com

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870. cjones@glysure.com

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. kara@kdvcommunications.com


'/>"/>
SOURCE GlySure Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlySure Secures $10.9 Million in Series C Financing Round
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
9. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
Breaking Medicine Technology:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):